NOTE: Although this activity is no longer certified for credit, we believe that it contains important information and hope you’ll review, print or email it to a colleague.
The Lung in COPD: What’s Left
0.50 AMA PRA Category 1 Credits
Utilize lung function testing to direct pharmacologic and adjunctive treatment approaches in moderate to severe COPD
This educational program is conceived and credited in accordance with ACCME's Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with pmiCME's Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of pmiCME.
||AMA PRA Category 1 Credits
||pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
||pmiCME designates this educational activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty and Editorial Board
R. Stokes Peebles, Jr., MD, FAAAAI, (Read Bio), Associate Professor of Medicine, Vanderbilt University, Nashville, TN
Carolyn Skowronski, PharmD, pmiCME
Financial Disclosure Statement(s)
Dr Peebles serves on the advisory board for Merck.
Ms Skowronski discloses that she holds stock in Merck.
Nizar N. Jarjour, MD, Educational Content Reviewer, discloses that he has consulting relationships with Asthmatx and Genentech-Novartis, and research funding from GlaxoSmithKline, Merck & Co., and MedImmune.
Steven Folstein, Director of Education, American Academy of Allergy, Asthma and Immunology, has no financial relationships to disclose.
pmiCME along with the American Academy of Allergy, Asthma & Immunology (AAAAI) are part of the ACES (Asthma and COPD Education Solutions) Consortium. This national CME initiative is a coordinated effort to improve the standards of care for patients with non-contagious chronic respiratory conditions. Funding for this initiative is obtained from multiple sources including commercial support. Receipt of these funds is project based and acknowledged by the partner organizations that are responsible for those identified projects.
pmiCME and AAAAI receive funding from GlaxoSmithKline in support of this educational activity, which is part of the ACES Consortium initiative.
American Academy of Allergy, Asthma & Immunology
pmiCME and AAAAI, through the University of North Texas Health Science Center at Fort Worth, received funding from GlaxoSmithKline in support of this educational activity, which is part of the ACES Consortium initiative.
Instructions for Obtaining Credit:
Complete this activity. Answer the questions in the attached posttest and evaluation. Click on "claim credit" and follow the instructions to print out the credit certificate.
Computer System Requirements:
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, or M|C Communications, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.